VEGF

money flying in
Biotech

Minghui raises $131M to fund JAK inhibitor launch, ADC trials

Minghui has secured $131 million for what the company describes as a “pre-IPO” round to fuel the potential launch of its eye drug in China.
James Waldron Aug 7, 2025 8:15am
graphic image of China flags overlapping with US flags

Instil's licensed PD-L1xVEGF bispecific shows promise in China

Jul 31, 2025 2:10pm
Close-up of Benjamin Franklins eyes peering through hundred dollar bills

BMS inks $11B biobucks BioNTech deal to join bispecific rush

Jun 2, 2025 8:59am
hot

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific

May 20, 2025 4:47am
iris eye eyeball eye art

Kodiak resurrects eye drug after ph. 3 data renew approval plans

Nov 6, 2023 8:40am
Moderna manufacturing site

Clean up on IL-2: Moderna mops up autoimmune asset

Aug 3, 2022 10:59am